Precision medicine aims at offering each patient an individualized treatment based on a deep analysis of the biological characteristics of the patient and the disease. The MSTARS research core in Berlin fosters precision medicine by establishing a mass spectrometry based platform in the clinics that allows standardized and high throughput analysis of patient material to support therapy recommendations. The disease foci of MSTARS are different cancer entities (e.g. head and neck squamous cell carcinoma, leukemia, ovarian cancer, neuroblastoma, prostate cancer) and inflammatory diseases (e.g. myocarditis, chronic liver diseases).
The consortium analyzes biosamples by mass spectrometry or mass spectrometry-coupled imaging based technologies to characterize the proteome and metabolome. Bioinformaticians integrate the acquired data and include already existing omics data, such as genomics and transcriptomics, striving for the identification of biomarkers and signatures for therapy resistances. The acquired knowledge is directly brought back into the clinics supporting future clinical study design and therapeutic decisions.
MSTARS
Targeting Treatment Resistance
Prof. Dr. Ulrich Keilholz
Charité - Universitätsmedizin Berlin, Charité Comprehensive Cancer Center
Prof. Dr. Matthias Selbach
Max Delbrück Center for Molecular Medicine, Proteome Dynamics
Prof. Dr. Markus Ralser
Charité - Universitätsmedizin Berlin, Institute of Biochemistry
Prof. Dr. Dipl.-Phys. Frederick Klauschen
Charité - Universitätsmedizin Berlin, Institute of Pathology
Prof. Dr. Dieter Beule
Berlin Institute of Health, Core Unit Bioinformatics
Prof. Dr. Nils Blüthgen
Charité - Universitätsmedizin Berlin, IRI Life Sciences
Dr. Fabian Coscia
Max Delbrück Center for Molecular Medicine, Spatial Proteomics
Dr. Vadim Demichev
Charité - Universitätsmedizin Berlin, Institute of Biochemistry
Dr. Stefan Kempa
Max Delbrück Center for Molecular Medicine, Proteomics and Metabolomics Platform
Dr. Jennifer Kirwan
Berlin Institute of Health, Core Unit Metabolomics
Dr. Oliver Klein
Berlin Institute of Health, Center for Regenerative Therapies
Dr. Philipp Mertins
Max Delbrück Center for Molecular Medicine, Berlin Institute of Health, Core Unit Proteomics
Dr. Michael Mülleder
Charité – Universitätsmedizin Berlin, Core Facility High Throughput Mass Spectrometry
Prof. Dr. Ingeborg Tinhofer-Keilholz
Charité - Universitätsmedizin Berlin, Department of Radiation Oncology and Radiotherapy
Prof. Dr. Elena Ioana Braicu
Charité - Universitätsmedizin Berlin, Department of Gynecology
Prof. Dr. Lars Bullinger
Charité - Universitätsmedizin Berlin, Department of Hematology, Oncology, and Tumorimmunology
PD Dr. Hedwig Deubzer
Charité - Universitätsmedizin Berlin, Department of Pediatric Oncology and Hematology
Dr. Dr. Christian Doll
Charité - Universitätsmedizin Berlin, Department for oral and maxillofacial surgery
Prof. Dr. Angelika Eggert
Charité - Universitätsmedizin Berlin, Department of Pediatric Oncology and Hematology
PD Dr. Konrad Klinghammer
Charité - Universitätsmedizin Berlin, Department of Hematology, Oncology, and Tumorimmunology
Prof. Dr. Il-Kang Na
Charité - Universitätsmedizin Berlin, Department of Hematology, Oncology and Cancer Immunology
PD Dr. Bernhard Ralla
Charité - Universitätsmedizin Berlin, Department of Urology
Prof. Dr. Thorsten Schlomm
Charité - Universitätsmedizin Berlin, Department of Urology
Prof. Dr. Jalid Sehouli
Charité - Universitätsmedizin Berlin, Department of Gynecology
Prof. Dr. Dr. Frank Tacke
Charité - Universitätsmedizin Berlin, Department of Hepatology and Gastroenterology
Prof. Dr. Carsten Tschöpe
Charité - Universitätsmedizin Berlin, Department of Cardiology
Prof. Dr. Dipl. Ing. Sophie Van Linthout
Berlin Institute of Health, Center for Regenerative Therapies
Dr. Joachim Weischenfeldt
Charité - Universitätsmedizin Berlin, Department of Urology
MSTARS
Charité - Universitätsmedizin Berlin
Charité Comprehensive Cancer Center
Charitéplatz 1
10117 Berlin
Germany